• arcosenautic@lemmy.world
    link
    fedilink
    English
    arrow-up
    1
    ·
    2 years ago

    Anyone with a proper background would be kind enough to speculate whether this could lead to a possible cure?

    • Higgs boson@dubvee.org
      link
      fedilink
      English
      arrow-up
      1
      ·
      2 years ago

      I’m not in this field, but I mean, this one seems like all the other headlines we’ve read about on this topic, only for them to be dead ends. Mouse models are notoriously fraught, especially in the Alzheimer’s context. Wake me up when they have treated humans in vivo.

        • redisdead@lemmy.world
          link
          fedilink
          arrow-up
          1
          ·
          2 years ago

          I wouldn’t call it a dead end. It’s the kind of small discoveries that, when put together with all the past and future small discoveries, will eventually lead to progress.

  • someguy3@lemmy.world
    link
    fedilink
    arrow-up
    1
    ·
    2 years ago

    The molecule, DDL-920, works differently from recent FDA-approved drugs for Alzheimer’s disease such as lecanemab and aducanumab, which remove harmful plaque that accumulates in the brains of Alzheimer’s disease patients. While removing this plaque has been shown to slow the rate of cognitive decline, it does not restore memory and cognitive impairments.

    “They leave behind a brain that is maybe plaqueless, but all the pathological alterations in the circuits and the mechanisms in the neurons are not corrected,” Mody said.